Helen I. Torley: Yes. And I'll just add. When we put our guidance in January, that is highly informed by the guidance ranges that our partners all give us. And so we do take our judgment within those ranges they give us. And so I would say first quarter — Q4 and Q1 reporting really does reflect that input we get from the partners. They — definitely, we're seeing some acceleration in momentum. Now I talked at the beginning of my prepared remarks about having achieved 11 of the 14 catalysts. Those kind of catalysts can be hard to predict exactly. But Nicole mentioned the prefilled syringe. We will see argenx itself said that, that was already impacting even after just one quarter. We are early in the launch in CIDP, that's another example.